- Home
- WLYB vs VKTX Comparison
WLYB vs VKTX Comparison
Compare WLYB & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLYB
- VKTX
- Stock Information
- Founded
- WLYB 1807
- VKTX 2012
- Country
- WLYB United States
- VKTX United States
- Employees
- WLYB N/A
- VKTX N/A
- Industry
- WLYB Books
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- WLYB Consumer Discretionary
- VKTX Health Care
- Exchange
- WLYB Nasdaq
- VKTX Nasdaq
- Market Cap
- WLYB 2.3B
- VKTX 2.8B
- IPO Year
- WLYB N/A
- VKTX 2015
- Fundamental
- Price
- WLYB $43.26
- VKTX $27.14
- Analyst Decision
- WLYB
- VKTX Buy
- Analyst Count
- WLYB 0
- VKTX 12
- Target Price
- WLYB N/A
- VKTX $84.00
- AVG Volume (30 Days)
- WLYB 164.0
- VKTX 2.9M
- Earning Date
- WLYB 06-17-2025
- VKTX 07-23-2025
- Dividend Yield
- WLYB 3.57%
- VKTX N/A
- EPS Growth
- WLYB N/A
- VKTX N/A
- EPS
- WLYB 0.75
- VKTX N/A
- Revenue
- WLYB $1,703,491,000.00
- VKTX N/A
- Revenue This Year
- WLYB N/A
- VKTX N/A
- Revenue Next Year
- WLYB $1.13
- VKTX N/A
- P/E Ratio
- WLYB $51.06
- VKTX N/A
- Revenue Growth
- WLYB N/A
- VKTX N/A
- 52 Week Low
- WLYB $35.68
- VKTX $18.92
- 52 Week High
- WLYB $52.90
- VKTX $81.73
- Technical
- Relative Strength Index (RSI)
- WLYB 43.57
- VKTX 48.69
- Support Level
- WLYB $39.54
- VKTX $26.66
- Resistance Level
- WLYB $44.15
- VKTX $28.33
- Average True Range (ATR)
- WLYB 0.00
- VKTX 1.34
- MACD
- WLYB -0.08
- VKTX -0.12
- Stochastic Oscillator
- WLYB 0.00
- VKTX 32.21
About WLYB John Wiley & Sons Inc.
John Wiley & Sons Inc is one of the world's greatest publishers and a trusted leader in research and learning. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.